Form 8-K - Current report:
SEC Accession No. 0000950170-24-093945
Filing Date
2024-08-08
Accepted
2024-08-08 16:10:09
Documents
13
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kura-20240808.htm   iXBRL 8-K 45992
2 EX-99.1 kura-ex99_1.htm EX-99.1 126792
3 GRAPHIC img71811756_0.jpg GRAPHIC 6669
  Complete submission text file 0000950170-24-093945.txt   314379

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20240808.xsd EX-101.SCH 30905
15 EXTRACTED XBRL INSTANCE DOCUMENT kura-20240808_htm.xml XML 4709
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 241188359
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)